In contrast, treatment with irbesartan prevents ACE2 deficiency-mediated cardiac hypertrophy and myocardial ultrastructure injury in ACE2 mutant mice with elevation of the PPARγ level and suppression of the TGFβ−CTGF−ERK signaling. The gene discussed is ACE2; the disease is cardiac hypertrophy.